Recommendation of the Czech society of Endocrinology for the treatment of Cushing’s syndrome in adults
Authors:
M. Kršek 1; J. Čáp 2; V. Hána 1; J. Marek Za Výbor České Endokrinologické Společnosti České Lékařské Společnosti J. E. Purkyně 1
Authors place of work:
III. interní klinika – klinika endokrinologie a metabolizmu 1. lékařské fakulty UK a VFN Praha, přednosta prof. MU Dr. Štěpán Svačina, DrSc., MBA
1; IV. interní hematologická klinika Lékařské fakulty UK a FN Hradec Králové, přednosta doc. MU Dr. Pavel Žák, Ph. D.
2
Published in the journal:
Vnitř Lék 2013; 59(9): 819-827
Category:
Guidelines
Summary
Cushing’s syndrome is a rare disorder with variable aetiology which is connected with significantly increased morbidity and mortality. Therefore, early determination of correct aetiology and early treatment are essential for a decrease of morbidity and mortality of patients. Present article introduces review and current recommendation of Czech Society of Endocrinology for the treatment of Cushing’s syndrome.
Key words:
Cushing’s syndrome – treatment – recommendation
Zdroje
1. Cushing HW. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932; 50: 137– 195.
2. Lahera Vargas M, da Costa CV. Prevalence, etiology and clinical findings of Cushing’s syndrome. Endocrinol Nutr 2009; 56: 32– 39.
3. Bertagna X, Guignat L, Groussin L et al. Cushing’s disease. Best Pract Res Clin Endocrinol Metab 2009; 23: 607– 623.
4. Ross EJ, Linch DC. Cushing’s syndrome‑ Killing disease: Discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 2: 646– 649.
5. Newell‑Price J, Trainer P, Bessser M et al. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo‑ Cushing’s states. Endocr Rev 1998; 19: 647– 672.
6. Nieman LK, Chrousos GP, Kellner C et al. Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985; 61: 536– 540.
7. Nieman LK, Biller BM, Findling JW et al. The Diagnosis of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526– 1540.
8. Utz AL, Swearingen B, Biller BM. Pituitary surgery and postoperative management in Cushing’s disease. Endocrinol Metab Clin North Am 2005; 34: 459– 478.
9. McCance DR, Besser M, Atkinson AB. Assessment of cure after transsphenoidal surgery for Cushing’s disease. Clin Endocrinol 1996; 44: 1– 6.
10. Vladyka V, Liščák R, Šimonová G et al. Radiosurgical treatment of hypophyseal adenomas with the gamma knife: results in a group of 163 patients during a 5‑year period. Čas Lék Česk 2000; 139: 757– 766.
11. de Bruin C, Feelders RA, Lamberts SW et al. Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s syndrome. Rev Endocr Metab Disord 2009; 10: 91– 102.
12. Kam BL, Teunissen JJ, Krenning EP et al. Lutetium‑ labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012; 39 (Suppl 1): 103– 112.
13. Valimaki M, Pelkonen R, Porkka L et al. Long‑term results of adrenal surgery in patients with Cushing’s syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf) 1984; 20: 229– 236.
14. Young WF Jr, Thompson GB. Laparoscopic adrenalectomy for patients who have Cushing’s syndrome. Endocrinol Metab Clin North Am 2005; 34: 489– 499.
15. Berruti A, Terzolo M, Sperone P et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005; 12: 657– 666.
16. Fassnacht M, Libé R, Kroiss M et al. Adrenocortical carcinoma: a clinician’s update. Nature Rev Endocrinol 2011; 7: 323– 335.
17. McGahan J, Browning P, Brock J et al. Hepatic ablation using radiofrequency electrocautery. Invest Radiol 1990; 25: 267– 270.
18. de Baere T, Dufaux J, Roche A et al. Circulatory alterations induced by intra‑ arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. Radiology 1995; 194: 165– 170.
19. Bourdeau I, Lacroix A. Aberrant hormone receptors in adrenal Cushing’s syndrome. Curr Opin Endocrinol Diab 2002; 9: 230– 236.
20. Morris D, Grossman A. The medical management of Cushing’s syndrome. Ann NY Acad Sci 2002; 970: 119– 133.
21. Godboud A, Manavela M, Danilowicz K et al.Cabergoline monotherapy in the long‑term treatment of Cushing’s disease. Eur J Endocrinol 2010; 165: 709– 716.
22. Casulari LA, Naves LA, Mello PA et al. Nelson’s syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 2004; 62: 300– 305.
23. Pivonello R, Ferrone D, de Herder WW et al. Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endocrinol Metab 2007; 92: 65– 69.
24. Valassi E, Klibanski A, Biller BM. Clinical review: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010; 95: 1025– 1033.
25. Lamberts SW, Uitterlinden P, Klijn JM. The effect of the long‑acting somatostatin analogue SMS 201– 995 on ACTH secretion in Nelson’s syndrome and Cushing’s disease. Acta Endocrinol (Copenh) 1989; 120: 760– 766.
26. Hofland LJ, van der Hoek J, Feelders R et al.The multiligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005; 152: 645– 654.
27. Colao A, Petersenn S, Newell‑Price J et al. Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 2012; 366: 914– 924.
28. Castillo V, Giacomini D, Paez‑ Pereda M et al.Retinoic acid as a novel medical therapy for Cushing’s disease in dogs. Endocrinology 2006; 147: 4438– 4444.
29. Dang CN, Trainer P. Pharmacological management of Cushing’s syndrome: an update. Arq Bras Endocrinol Metabol 2007; 51: 1339– 1348.
30. Knight TE, Shikuma CY, Knight J. Ketoconazole‑induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol 1991; 25: 398– 400.
31. Verhelst JA, Trainer PJ, Howlett TA et al. Short and long‑term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 1991; 35: 169– 178.
32. Haak HR, Hermans J, van de Velde CJ et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in consecutive series of 96 patients. Br J Cancer 1994; 69: 947– 951.
33. Allolio B, Schulte HM, Kaulen D et al. Nonhypnotic low‑dose etomidate for rapid correction of hypercortisolaemia in Cushing’s syndrome. Klin Wochenschr 1988; 66: 361– 364.
34. Drake WM, Perry LA, Hinds CJ et al. Emergency and prolonged use of intravenous etomidate to control hypercortisolaemia in a patient with Cushing’s syndrome and peritonitis. J Clin Endocrinol Metab 1998; 83: 3542– 3544.
35. Feelders RA, de Bruin C, Pereira AM et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med 2010; 362: 1846– 1848.
36. Kršek M, Hána V et al. Cushingův syndrom. Praha: Galén 2006.
37. Kršek M. Cushingův syndrom a možnosti jeho řešení v roce 2012. Remedia 2012; 22: 386– 392.
38. Trainer PJ, Eastment C, Grossman A et al. The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing’s syndrome. Clin Endocrinol 1993; 39: 441– 443.
39. Lindsay JR, Jonklaas J, Oldfield EH et al. Cushing’s syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 2005; 90: 3077– 3083.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2013 Číslo 9
Najčítanejšie v tomto čísle
- Cold agglutinin disease – no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature
- Food intake regulation – 1st part
- Recommendation of the Czech society of Endocrinology for the treatment of Cushing’s syndrome in adults
- Regional migrating osteoporosis – a case report